We are live on ! Find out more
LBPS

4D Pharma PLC
LBPS

Delisted

LBPS was delisted on the 24th of June, 2022.

Back to rankings

10 hedge funds and large institutions have $2.03M invested in 4D Pharma PLC in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

43% more funds holding

Funds holding: 7 → 10 (+3)

9% more capital invested

Capital invested by funds: $1.87M → $2.03M (+$159K)

Holders
10
Holders Change
+3
Holders Change %
+42.86%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$132K
2
Morgan Stanley
Morgan Stanley
New York
+$94.4K
3
Capstone Investment Advisors
Capstone Investment Advisors
New York
+$63.5K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$49.5K
5
TRCT
Tower Research Capital (TRC)
New York
+$35.5K

Top Sellers

Rank Fund Capital Flow
1
SG
StoneX Group
New York
-$86.6K

LBPS Hedge Fund Activity: Q1 2022 in Review

10 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in 4D Pharma PLC (LBPS) for Q1 2022, worth a combined $2.03M — up 8.5% from $1.87M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new LBPS positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $132K. The largest seller was StoneX Group, exiting entirely with an estimated $86.6K sold.

  • 10 institutional investors held 4D Pharma PLC (LBPS) as of Q1 2022, up from 7 in Q4 2021.
  • Funds reported $2.03M of 4D Pharma PLC stock for Q1 2022, up 8.5% quarter-over-quarter.
  • 4 funds opened new 4D Pharma PLC positions in Q1 2022 and 1 closed out, a net change of +3 holders.
  • The largest 4D Pharma PLC buyer in Q1 2022 was Citadel Advisors, an estimated $132K added.
  • The largest 4D Pharma PLC seller in Q1 2022 was StoneX Group, an estimated $86.6K sold.

Based on aggregated 13F filings for Q1 2022.